Nighthawk Intersects 52.07 Metres of 7.72 g/t Gold (Uncut) and 31.45 Metres of 4.14 g/t Gold (Uncut) at Colomac - Supports Continuity and Expansion Potential of High-Grade Zone

TORONTO, ONTARIO--(- Sep 13, 2016) - Nighthawk Gold Corp. ("Nighthawk" or the "Company") (TSX VENTURE:NHK) is pleased to announce initial results from its ongoing 2016 drill program on its Indin Lake Gold Property in the Northwest Territories ("NWT") (Figure 1 / Table 1). In July 2016, the Company launched a 10,000 metre program (see July 5, 2016 news release) to advance delineation of the recently discovered high-grade gold mineralization at Zone 1.5 and to resume exploration for additional higher-grade domains, with the objective of expanding our current resource. Two drills are actively testing priority targets at both the Colomac and Goldcrest deposits. Results from 5 drillholes at Colomac Zone 1.5 are presented below.
Read more: Nighthawk Gold Corp ( NHK )

Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis

Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint
Preliminary safety findings show sparsentan was generally safe and well-tolerated
Conference call scheduled for today at 8:30 a.m. ET
SAN DIEGO, Sept. 07, 2016 -- Retrophin, Inc. (RTRX) today announced positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an approved pharmacologic treatment that often leads to end-stage renal disease. The study achieved statistical significance in the primary efficacy endpoint for the overall sparsentan treatment group, demonstrating a greater than two-fold reduction of proteinuria compared to irbesartan after the eight-week, double-blind treatment period.
Read more: Retrophin Inc ( RTRX )

Extension of Zone 25 to the Northwest at Sakami With Intersections of 1.62 g/t Au Over 64.50 Metres, Including 2.21 g/t Au Over 43.30 Metres and 3.46 g/t Au Over 11.50 Metres 

MONTREAL, QUEBEC--(Aug. 25, 2016) -Canada Strategic Metals Inc. ("Canada Strategic Metals" or "the Company") (TSX VENTURE:CJC)(YXEN.F)(CJCFF)andMatamec Explorations Inc. (TSX VENTURE:MAT)(MHREF) are pleased to report the results of the first of nine holes completed on the Northwest extension of Zone 25 (main zone) with an intersection of 1.62 g/t Au over 64.50 metres including 2.21 g/t Au over 43.30 metres and 3.46 g/t over 11.50 metres from hole PT-16-91 (see table below). These new results confirm the extension to the Northwest of the Zone 25 envelope of gold mineralization. The program consisted of nine holes for a total of 2,058 metres of drilling.
Read more: Canada Strategic Metals Inc ( CJC )

Spherix Enters Into Non-Binding Letter Of Intent with Privacy Messaging Pioneer DatChat

NEW YORK, Aug. 9, 2016 -- Spherix Incorporated (SPEX) –a company committed to the fostering of technology and the monetization of intellectual property, today announced that it has entered into a non-binding letter of intent ("LOI") to invest in DatChat Inc. – a pioneer in the secure (privacy) messaging industry – in exchange for an equity security interest in DatChat.  DatChat's patent-pending encryption technology allows users to secure their messages sent between mobile devices.  Earlier this year, DatChat announced that its technology offers an unprecedented level of privacy control for both individual and group messages.  According to DatChat, its app is the first privacy messaging app that provides the option to dictate how long sent messages are accessible on the recipient's phone and is the first to offer an option that will erase both sides of a conversation on both the sender and recipient's devices, even after the information is transmitted to another user.  Currently, the DatChat app is available in theiTunes® store.
Read more: Spherix Incorporated ( SPEX )

Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001

SOLANA BEACH, Calif., July 26, 2016 -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the US Food and Drug Administration (FDA) has conditionally accepted the proprietary brand name, “Gimoti,” for the Company’s product candidate, EVK-001 (metoclopramide nasal spray). A request for proprietary name review for Gimoti will be included if and when Evoke submits a New Drug Application (NDA) for the product candidate.
The name Gimoti (pronounced “jye-MOH-tee”) was developed in compliance with the FDA’s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names (issued in February 2010).  The development program, which included research with physicians and pharmacists, as well as an international name assessment, confirmed Gimoti is a proprietary name with strong marketing potential that is also consistent with the FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. 
Read more: Evoke Pharma Inc ( EVOK )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker